Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy

Inclusion Criteria:

• Within the United States or Canada.

• Qualify as a prospective enrollment, defined as currently pregnant.

• A diagnosis of migraine by the patient's health care provider (HCP).

• Provide contact information for the participant and her and her infant(s)', ifapplicable, HCPs.

• Authorize their HCP(s) to release maternal and infant medical information to theregistry, upon request.

• Provide sufficient information to confirm eligibility for 1 of following:

• Ubrelvy-exposed women with migraine: documented information indicating that atleast 1 dose of Ubrelvy was taken during pregnancy, including the estimatednumber of administrations per trimester.

• Qulipta-exposed women with migraine: documented information to indicating thatat least 1 dose of Qulipta was taken during pregnancy, including start and stopdate(s) of administration.

• Internal comparator: Ubrelvy/Qulipta-unexposed pregnant women with migraine:documented information indicating that they have, a) never taken Ubrelvy and/orQulipta, or b) discontinued Ubrelvy 2 days prior or Qulipta 5 days prior toconception.

Exclusion Criteria:

• Documentation of exposure to any gepants (acute or preventive) other than Ubrelvyand Qulipta, or CGRP monoclonal antibodies, from 5 halflives of the respectivetreatment prior to conception or at any point during pregnancy before enrollment.

• Women who are no longer pregnant (retrospective cases women for whom the pregnancyhas already ended, and the outcome of pregnancy is known at the time of enrollment).

• For further clarification of inclusion/exclusion please contact the investigator tothe end of this section in case anything is unclear to a potential patient, etc